BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,088 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
Ceeto Capital Group, LLC 7,800$629,0000.35%
Tempus Wealth Planning, LLC 3,000$241,0000.35%
Hartford Financial Management Inc. 14,455$1,162,0000.34%
Red Cedar Capital, LLC 4,893$393,0000.34%
Bank Pictet & Cie (Europe) AG 75,443$6,067,0000.34%
DUMONT & BLAKE INVESTMENT ADVISORS LLC 11,028$887,0000.34%
Glenview Capital Management 132,623$10,666,0000.34%
Quadrature Capital Ltd 71,973$5,787,0000.33%
State of Alaska, Department of Revenue 332,099$26,706,0000.33%
HERON FINANCIAL GROUP, LLC 5,076$409,0000.33%
PERKINS CAPITAL MANAGEMENT INC 4,367$351,0000.32%
BANK PICTET & CIE (ASIA) LTD 10,229$823,0000.32%
Tuttle Capital Management, LLC 5,714$460,0000.32%
BNP Paribas Asset Management Holding S.A. 689,242$55,429,0000.32%
PRUDENTIAL PLC 778,200$62,583,0000.31%
Vestcor Inc 83,642$6,726,0000.31%
Point View Wealth Management, Inc. 8,133$654,0000.31%
MARTINGALE ASSET MANAGEMENT L P 320,648$25,787,0000.31%
State of Tennessee, Department of Treasury 823,838$66,253,0000.31%
BRASADA CAPITAL MANAGEMENT, LP 29,900$2,404,0000.31%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.